Trending

Ipsen

Ipsen on neurotoxin research: the pharmaphorum podcast

Ipsen on neurotoxin research: the pharmaphorum podcast

For episode 7 of the pharmaphorum podcast I spoke to Ipsen’s Philippe Picaut about neurotoxin research, with a

X

Ipsen on neurotoxin research: the pharmaphorum podcast

https://pharmaphorum.com/podcast/ipsen-neurotoxin-research/

Ipsen launches new syringe for rare disease blockbuster

Ipsen launches new syringe for rare disease blockbuster

Ipsen will be launching a new pre-filled syringe for its blockbuster rare disease drug Somatuline (lanreotide) in the

X

Ipsen launches new syringe for rare disease blockbuster

https://pharmaphorum.com/news/ipsen-launches-new-syringe-for-rare-disease-blockbuster/

Ipsen to buy rare disease firm Clementia for up to $1.31bn

Ipsen to buy rare disease firm Clementia for up to $1.31bn

France’s Ipsen has agreed to buy Canadian rare diseases biotech Clementia Pharmaceuticals in a deal worth up to

X

Ipsen to buy rare disease firm Clementia for up to $1.31bn

https://pharmaphorum.com/news/ipsen-to-buy-rare-disease-firm-clementia-for-up-to-1-31bn/

Chinese patients to get new drugs before UK after Brexit – says CEO

Chinese patients to get new drugs before UK after Brexit – says CEO

US, European, Japanese and Chinese patients could get novel medicines ahead of patients in the UK after Brexit,

X

Chinese patients to get new drugs before UK after Brexit – says CEO

https://pharmaphorum.com/news/chinese-patients-new-drugs-before-uk-brexit-ceo/

Ipsen warns over medicine supplies amid Brexit uncertainty

Ipsen warns over medicine supplies amid Brexit uncertainty

France’s Ipsen has become the latest pharma company to warn about the impact of Brexit on the pharma

X

Ipsen warns over medicine supplies amid Brexit uncertainty

https://pharmaphorum.com/news/ipsen-warns-over-medicine-supplies-amid-brexit-uncertainty/

EU approves Ipsen’s Cabometyx in second line liver cancer

EU approves Ipsen’s Cabometyx in second line liver cancer

The European Commission has approved Ipsen’s Cabometyx for liver cancer, in adults previously treated with Bayer’s Nexavar. The

X

EU approves Ipsen’s Cabometyx in second line liver cancer

https://pharmaphorum.com/news/european-commission-cabometyx/

EU regulators back Ipsen cancer drug in new liver cancer use

EU regulators back Ipsen cancer drug in new liver cancer use

Ipsen’s bid to build a cancer franchise around its Cabometyx (cabozantinib) is gathering pace after European regulators backed

X

EU regulators back Ipsen cancer drug in new liver cancer use

https://pharmaphorum.com/news/eu-regulators-cabometyx-liver/

Ipsen appoints new general manager for the UK & Ireland

Ipsen appoints new general manager for the UK & Ireland

The French pharma company appointed a new general manager for its UK and Ireland office, Asad Mohsin Ali,

X

Ipsen appoints new general manager for the UK & Ireland

https://pharmaphorum.com/news/ipsen-appoints-new-general-manager/

Scotland’s NHS to fund Ipsen cancer diarrhoea drug

Scotland’s NHS to fund Ipsen cancer diarrhoea drug

Decision welcomed as step forward for patients

X

Scotland’s NHS to fund Ipsen cancer diarrhoea drug

https://pharmaphorum.com/news/scotlands-nhs-ipsen-cancer-drug/

1 2 3

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com